Last updated: 2026-09-16 09:45:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Adaptive Biotechnologies Corporation (ADPT) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $26.86, with a market capitalisation of $3.95B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $12.00 to $27.34. This page covers its latest market performance, valuation, price trends and company information.
$3.95B | |
$26.34 | |
$123.97 | |
$0.90 | |
$26.68 | |
1.22K | |
2.77M | |
-- | |
$27.34 | |
$12.00 | |
-- | |
-- |
Adaptive Biotechnologies Corporation (ADPT) is trading at $26.86 in pre-market trading as of 2026-09-16 09:01:00, up 0.67% ($0.18) from the previous close of $26.68
Pre-market trading shows how investors are pricing ADPT before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Adaptive Biotechnologies Corporation (ADPT) moved from $24.28 to $26.86, representing a gain of 10.62% ($2.58).
The stock traded between $23.53 and $27.34 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 1.72 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 96.9%
ADPT is currently trading at $26.86, placing it 96.9% of the way from its 52-week low of $12.00 to its 52-week high of $27.34. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 624 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Adaptive Biotechnologies Corporation (ADPT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.